Insider filing · PASG

Lynx1 Capital Management LP bought $264K of Passage Bio (PASG)

Executed Nov 25 2024, disclosed Nov 27 2024, 2 days later.

Over the 21 trading sessions from the disclosed entry session (Nov 27 2024), the stock returned -16.6% (delay-adjusted); from the execution session (Nov 25 2024), +28.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

LL Lynx1 Capital Management LP 10% owner profile →

Lynx1 Capital Management LP (10% owner) filed 5 Form 4 reports as a reporting entity in the trailing twelve months (5 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Passage Bio, Inc. (PASG). Across 5 priced purchase filings, the average 21-session return was +14.0% from execution and +10.1% from disclosure (delay-adjusted; derived). The largest single filing was $9.8M of CGEM (1,459,641 sh across 3 lots, as filed), executed Oct 8 2025.

PASG Passage Bio, Inc. PASG · Healthcare · 6 filings in 24 months ticker →

Healthcare · Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→